SC10: In vitro and in vivo Modeling for Cancer Immunotherapy
WEDNESDAY, JUNE 19 | 6:15 - 9:15pm
ABOUT THIS COURSE: This short course will describe the use of cutting-edge models to study human tumor biology, including both in vivo and in vitro approaches to advance our understanding of interactions between human
immune systems and the tumor microenvironment. The use of humanized mice to study tumor biology will be discussed, including a description of the unique models available currently, highlighting the strengths and limitations of the models and the specific
application of humanized mice in the field of cancer immunotherapy. The development and use of 3D models and patient-derived organoids will also be discussed, including a description of the technologies needed to establish these models and their application
to study tumor physiology, growth and specific therapies. Key concepts that will be emphasized in the course include the development of optimal strategies and study designs to effectively interrogate questions focused on immuno-oncology.
Michael Brehm, PhD,
Assistant Professor, Diabetes Center of Excellence, Program in Molecular Medicine, University of Massachusetts Medical School
Dr. Brehm received his PhD from the Department of Microbiology and Immunology at the Pennsylvania State University College of Medicine. He is currently an Assistant Professor in the Program in Molecular Medicine at the University of Massachusetts Medical
School and a member of the UMass Diabetes Center of Excellence. Dr. Brehm’s research program is focused on understanding how human effector T cells are regulated, and his laboratory is actively using “humanized” mice to model human
T cell responses. Dr. Brehm has published over 70 manuscripts and reviews and is supported by funding from the JDRF, NIAID, NIDDK and the Helmsley Charitable Trust.
Barbara Joyce-Shaikh, Associate Principal Scientist, Merck Research Laboratories
Barbara is a Discovery research scientist with 18 years of experience working in the pharmaceutical industry. She utilizes multiple platforms to study pre-clinical antibodies and small molecules to establish in vivo efficacy and in vitro mechanism.
Aaron Goldman, PhD, Director, Drug Resistance Group, Brigham and Women's Hospital, Faculty and Instructor in Medicine, Harvard Medical School, Breast Cancer Alliance Early Career Investigator, Harvard-MIT Health Sciences and Technology; Director
of R&D & Head of Immuno-Oncology, Mitra Biotech
Our research at Brigham and Women's Hospital and Harvard Medical School is focused on developing an understanding of how cancer cells respond and resist cancer chemo and immunotherapies. We seek to fully interrogate the entire tumor ecosystem, which encompasses
tumor cells, the microenvironment around it, and even the role that normal cells contribute to the progression of cancer under drug pressure. To do this, we engage a unique interdisciplinary team of scientists to provide a complete picture of drug
response and resistance in a patient's tumor.